Clot Waveform of APTT Has Abnormal Patterns in Subjects with COVID-19

Takuya Shimura  
The University of Tokyo Hospital, Tokyo, Japan

Makoto Kurano  (kurano-tky@umin.ac.jp)  
The University of Tokyo Hospital, Tokyo, Japan

Yoshiaki Kanno  
The University of Tokyo Hospital, Tokyo, Japan

Mahoko Ikeda  
The University of Tokyo Hospital, Tokyo, Japan

Koh Okamoto  
The University of Tokyo Hospital, Tokyo, Japan

Daisuke Jubishi  
The University of Tokyo Hospital, Tokyo, Japan

Sohei Harada  
The University of Tokyo

Shu Okugawa  
The University of Tokyo Hospital

Kyoji Moriya  
The University of Tokyo Hospital

Yutaka Yatomi  
The University of Tokyo Hospital

Research Article

Keywords: COVID-19, coagulopathy, APTT clot waveform, fibrinogen

DOI: https://doi.org/10.21203/rs.3.rs-43405/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

In Coronavirus disease 2019 (COVID-19) subjects, recent evidence suggests the presence of unique coagulation abnormalities. In this study, we performed clot waveform analyses to investigate whether specific modulations are observed in COVID-19 subjects. We analyzed the second derivative of the absorbance in routine APTT tests performed using an ACL-TOP system. We observed high frequencies of abnormal patterns in APTT second-derivative curves that could be classified into an early shoulder type, a late shoulder type, or a biphasic type, high maximum first-derivative and second-derivative peak levels, and a low minimum second-derivative peak level in COVID-19 subjects. These modulations were not observed in subjects with disseminated intravascular coagulation. These abnormal patterns are also observed in patients with lupus anticoagulant, hemophilia, or factor IX deficiency. The plasma fibrinogen levels might also be involved in the abnormal APTT waveforms, especially the high maximum first-derivative and second-derivative peak levels. The abnormal patterns in the APTT second-derivative curves appear with highest frequency at around 2 weeks after the onset of COVID-19 and were not associated with the severity of COVID-19. These results suggest the possible presence of a specific abnormal coagulopathy in COVID-19.

Introduction

Coronavirus disease 2019 (COVID-19), caused by the 2019 novel coronavirus (SARS-CoV-2), is spreading and threatening populations worldwide. Acute respiratory distress syndrome and multi-organ dysfunction in COVID-19 causes mortality in patients with severe COVID-19. Along with these complications, the activation of coagulation is one of the severe complications of COVID-19. Disseminated intravascular coagulation (DIC), which is commonly associated with sepsis, can be observed in patients with severe COVID-19. However, the pattern of DIC in COVID-19 patients reportedly differs from that in subjects with sepsis. In COVID-19 subjects, an elevation in D-dimer is prominent, while thrombocytopenia and the prolongations of PT and APTT are milder. Moreover, a high frequency of venous and arterial thromboembolism is observed, even in subjects with mild COVID-19. These unique patterns of laboratory data and the high incidence of thromboembolism suggest that coagulation abnormalities might exist in subjects with COVID-19.

At present, several mechanisms have been proposed to explain the mechanism of abnormal coagulopathy observed in COVID-19 subjects. One proposed mechanism is that SARS-CoV2 infects endothelial cells and is then prone to cause endotheliitis, which results in the acceleration of coagulation. Theoretically, hypo-oxygenation caused by pneumonia can exacerbate endothelial injuries. Another possible mechanism is the involvement of inflammation. Severe COVID-19 is associated with an elevation of inflammatory cytokines, which can increase the expression of tissue factor and the suppression of anticoagulant factors. Recently, lupus anticoagulation has frequently been observed in COVID-19 subjects, and this could also be another possible mechanism of abnormal coagulopathy.
However, the exact mechanisms responsible for the coagulopathy observed in COVID-19 remain to be elucidated.

To clarify the underlying mechanisms of abnormal coagulation in COVID-19, one good strategy would be to measure the various factors involved in the pathophysiology of coagulation, such as coagulants, anti-coagulants, fibrolytic factors, platelet-stimulating factors, and endothelial derivatives, in addition to performing routine coagulation function tests. In this study, we focused on the clot waveforms of PT and APTT. Clot waveform analyses provide us with information on fibrin abnormalities and the speed and acceleration of clot formation. Several studies have proposed that clot formation curves can suggest some specific diseases. In the present study, therefore, we aimed to investigate the clot waveforms of APTT in COVID-19 subjects to investigate whether abnormal patterns of clot formation are observable using these laboratory tests.

**Methods**

**Subjects.**

We analyzed the clot waveforms observed for 137 routine APTT tests performed using specimens from 26 COVID-19 subjects confirmed with RT-PCR using primers specific for SARS-CoV-2s. We also performed APTT clot waveform analyses using specimens from 20 normal subjects, 2 subjects with lupus anticoagulant, 10 DIC patients with sepsis, 20 subjects taking warfarin, 20 subjects treated with heparin, and 7 subjects with a congenital absence of specific coagulation factors (FVII deficiency, n = 1; hemophilia B homo-type, n = 1; hemophilia A hetero-type, n = 1; hemophilia A homo-type, n = 3; von Willebrand disease, n = 1). COVID-19 subjects were categorized into three groups: those requiring no oxygen therapy (“mild” group), those requiring oxygen treatment without mechanical respiratory ventilation support (“moderate” group), and those requiring mechanical respiratory ventilation support (“severe” group). The current study was performed in accordance with the ethical guidelines of the Declaration of Helsinki. Informed consent was obtained in the form of an opt-out on the website. The study design was approved by The University of Tokyo Medical Research Center Ethics Committee (approval number, 3683).

**Clot waveform analyses.**

The APTT tests were performed using the ACL APTT SyntheSis kit and the ACL-TOP 700 hemostasis testing system (Instrumentation Laboratory, Bedford, Massachusetts, USA), which provides three types of curves: a curve showing the changes in absorbance observed during the APTT measurement; a curve presenting the first derivative of the absorbance, corresponding to the coagulation velocity; and a curve showing the second derivative of the absorbance, corresponding to the coagulation acceleration. We investigated the presence of a biphasic pattern in the clot waveform for the second derivative of the
absorbance as well as the parameters calculated from the clot waveform, the maximum peak of the first derivative, and the maximum and minimum peaks of the second derivative.

**Statistical analyses.**

All the data were analyzed statistically using SPSS (Chicago, IL). The results were expressed as dot plots or the mean ± S.D. The differences in the existence of an abnormal clot waveform were assessed using a Chi square test. Values for more than three groups were compared using the Kruskal-Wallis test followed by the Games Howell test as a post-hoc test. Correlations were examined using the Spearman correlation test. *P* values less than 0.05 were regarded as statistically significant in all the analyses.

**Results**

**High frequency of abnormal patterns for second-derivative curves of APTT clot waveforms in COVID-19 subjects.**

We found that the second-derivative curves of APTT tests in several COVID-19 subjects showed abnormal patterns: compared with those for normal subjects (Figure 1A), the abnormal APTT second-derivative curves were classifiable into a biphasic type, an early shoulder type, and a late shoulder type (Figure 1B–D). In other subjects suffering from other coagulopathies, these abnormal waveform patterns were rarely observed. We did not observe abnormal patterns in subjects with DIC or in those treated with heparin (Figure 1E and Supplementary Figure S1A). The early shoulder pattern was observed in subjects with lupus anticoagulant (Figure 1F) and in one subject with FIX deficiency (Supplementary Figure S1B), while the biphasic pattern was observed in one subject with hemophilia and one subject taking warfarin (Supplementary Figure S1C and S1D).

We investigated the frequency of abnormal second-derivative curves by analyzing all the APTT tests together, by analyzing the APTT tests performed when the D-dimer or CRP level was at a maximum during the time course, or by analyzing the APTT tests performed when the subjects visited the hospital for the first time. As shown in Table 1, the frequency of abnormal second-derivative curves was significantly high among the COVID-19 subjects in all the models that were investigated. In addition to the abnormal patterns, the maximums of the first-derivative peak and the second-derivative peak were higher and the minimum of the second-derivative peak was lower among the COVID-19 subjects in all the analyzed models (Figure 2). Regarding related laboratory data, the APTT levels and the D-dimer levels were significantly higher in the COVID-19 subjects than in the normal subjects, while they were not different between the DIC subjects and the COVID-19 subjects (Supplementary Figure S2A and C). The plasma fibrinogen levels were significantly higher in the COVID-19 subjects than in the DIC subjects (Supplementary Figure S2B).
Association between plasma fibrinogen levels and abnormal APTT second-derivative curves in COVID-19 subjects.

Next, we investigated the factors associated with the abnormal APTT second-derivative curves. First, we investigated the potential associations between abnormal APTT second-derivative waveforms and other related factors. We observed that the APTT second-derivative waveforms and the fibrinogen levels were both higher in the specimens with an early shoulder or biphasic pattern and that the CRP levels were higher in the specimens with a biphasic pattern, compared with those with a normal pattern, while the D-dimer levels and the platelet counts did not differ according to the waveform pattern (Figure 3 and Supplementary Figure S3D). The maximum first-derivative peak and the maximum second-derivative peak were significantly higher in the specimens with a biphasic pattern (Supplementary Figure S3A–C).

Regarding the association between the maximum first-derivative peak or the maximum or minimum second-derivative peak and other laboratory data, we found rather strong associations between the maximum first-derivative peak or the maximum second-derivative peak and the plasma fibrinogen levels and a moderate association between the minimum second-derivative peak and the APTT level (Figure 4 and Supplementary Figure S4). Although abnormal APTT waveforms were also observed in subjects without elevated fibrinogen levels, these results suggest that the appearance of abnormal APTT waveforms in COVID-19 subjects might be associated with pathological situations involving an increase in fibrinogen.

Appearance of abnormal patterns in APTT second-derivative curves with highest frequency at around 2 weeks after the onset of COVID-19.

Next, we investigated the time course of the APTT second-derivative curves of COVID-19 subjects. Figure 5A–D shows the time course of the APTT second-derivative curves for a COVID-19 subject who suffered from severe COVID-19 followed by septic DIC after the disappearance of SARS-CoV2. The time course for the APTT second-derivative curves supports the idea that the appearance of a biphasic pattern might be rather specific to COVID-19.

Figure 5E–H shows the time course for the incidence of an abnormal pattern in APTT second-derivative curves and the maximum first-derivative peak or the maximum or minimum second-derivative peak. Considering that the data points were limited to tests performed at more than 33 days after the onset of COVID-19, the appearance of an abnormal pattern was highest at around 2 weeks after the estimated onset of COVID-19, while the maximum first-derivative peak and the maximum and minimum second-derivative peaks did not show any obvious changes over time.
Lack of association between abnormal patterns in APTT second-derivative curves and the severity of COVID-19.

Lastly, we investigated whether the existence of a biphasic pattern for the APTT second-derivative curve was associated with any of the clinical characteristics that were examined in this study. As shown in Table 2, no association between the severity of the subjects and the existence of an abnormal APTT second-derivative waveform was seen. We did not observe any significance differences in the appearance of an abnormal APTT pattern between mild to moderate cases and severe cases, at the time point when the D-dimer or CRP level reached a maximum during the time course, or at the time of the subjects’ initial hospital visit (data not shown). We also did not find any significance difference in the maximum first-derivative peak or the maximum or minimum second-derivative peak according to severity (Supplementary Figure S5).

Discussion

Abnormal coagulation is emerging as a severe complication in COVID-19 subjects. In addition to a condition resembling DIC, a high incidence of thromboembolism can lead to impairments in COVID-19 patients. In the present study, we analyzed the clot waveforms for APTT tests and found a high frequency of abnormal patterns in APTT second-derivative curves, high maximum first-derivative and second-derivative peak levels, and a low minimum second-derivative peak level in COVID-19 subjects.

Regarding the abnormal APTT second-derivative waveforms, these patterns are sometimes observed in specific deficiencies or inhibitions of coagulation factors, such as hemophilia, or the presence of lupus anticoagulant\textsuperscript{15,16}. Concordantly with previous reports, we observed the presence of biphasic patterns in patients with lupus anticoagulant, hemophilia, or factor IX deficiency and in one subject who was taking warfarin (Table 1). Regarding DIC, contrary to a previous report using other coagulation parameters\textsuperscript{17}, we did not observe any abnormal patterns in the subjects with DIC. Another group using the same parameters as us has reported similar results\textsuperscript{18}. The present of lupus anticoagulant has been reported in COVID-19 subjects\textsuperscript{11}. However, since the APTT is prolonged to a greater degree in patients with lupus anticoagulant and since the appearance of an abnormal pattern was rare among subjects taking warfarin (1/20), the presence of lupus anticoagulant or a decrease in vitamin K-dependent coagulation factors might not explain, at least not entirely, the mechanisms responsible for the biphasic pattern observed in COVID-19 subjects. One possible mechanism is the presence of an inhibitor to specific coagulation factors or a severe consumption of these factors, possibly explaining the appearance of a biphasic pattern in APTT second-derivative curves\textsuperscript{15}. However, the appearance of a biphasic pattern was not associated with the severity of COVID-19 (Table 2), which is not concordant with a possible mechanism in which the consumption of specific coagulation factors results in the abnormal APTT second-derivative waveforms. Another possible mechanism is an abnormality in von Willebrand Factor (VWF), although we did not observe an abnormal waveform in the single subject with von Willebrand disease who was examined in the present study. Tokunaga et al. reported that the plasma
level of VWF directly influences the abnormal biphasic patterns of APTT second-derivative curves\textsuperscript{14}. VWF is produced and stored in endothelial cells and it increases during thrombogenicity, forming bridges between sub-endothelial collagen and platelets\textsuperscript{19}, while it protects FVIII against proteolytic inactivation by activated protein C and S\textsuperscript{20}. Since endothelial inflammation and injuries are often observed in COVID-19\textsuperscript{9}, an impairment in VWF function because of an abnormal quality, abnormal local circumstance, or abnormal quantity of VWF might occur in COVID-19. At present, only one report has reported that plasma VWF levels, together with FVIII, were higher in COVID-19 subjects\textsuperscript{21}. The elongation of the APTT and high fibrinogen and CRP levels might be associated with the presence of an abnormal APTT second-derivative waveform; however, specimens with normal APTT, fibrinogen, or CRP values sometimes exhibit abnormal APTT second-derivative waveforms, suggesting that these phenomena or molecules are not the direct causes of the abnormal waveforms.

We also observed high maximum first-derivative and second-derivative peak levels and a low minimum second-derivative peak level in COVID-19 subjects. These results suggest that the speed and acceleration of clot formation were relatively high in APTT tests performed using specimens from COVID-19 subjects. Considering that these parameters are strongly correlated with plasma fibrinogen levels (Figure 4) and that fibrinogen theoretically enhances the speed and acceleration of clot formation, high fibrinogen levels could explain these modulations in COVID-19 subjects. Another possibility is the involvement of several phospholipids or factors that accelerate the response to phospholipids in APTT assays, since an APTT assay monitors clot formation arising from a response to phospholipids. Actually, HCoV-229E, another type of coronavirus, reportedly disturbs phospholipid homeostasis in infected cells\textsuperscript{22}.

Since this study examined APTT clot waveforms retrospectively, we could not elucidate the exact underlying mechanism responsible for the abnormal APTT second-derivative curves observed in COVID-19 subjects. However, the results of this study suggest the possible presence of a specific abnormal coagulopathy in COVID-19.

References

1. Tang, N., Li, D., Wang, X. & Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. \textit{J Thromb Haemost} \textbf{18}, 844-847, doi:10.1111/jth.14768 (2020).

2. Chen, N. \textit{et al.} Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. \textit{Lancet} \textbf{395}, 507-513, doi:10.1016/S0140-6736(20)30211-7 (2020).

3. Wang, D. \textit{et al.} Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. \textit{JAMA}, doi:10.1001/jama.2020.1585 (2020).
4 Lodigiani, C. *et al.* Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res* **191**, 9-14, doi:10.1016/j.thromres.2020.04.024 (2020).

5 Paranjpe, I. *et al.* Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. *J Am Coll Cardiol*, doi:10.1016/j.jacc.2020.05.001 (2020).

6 Tang, N. *et al.* Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* **18**, 1094-1099, doi:10.1111/j.th.14817 (2020).

7 Cui, S., Chen, S., Li, X., Liu, S. & Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost*, doi:10.1111/jth.14830 (2020).

8 Thachil, J. *et al.* ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Haemost* **18**, 1023-1026, doi:10.1111/jth.14810 (2020).

9 Varga, Z. *et al.* Endothelial cell infection and endotheliitis in COVID-19. *Lancet* **395**, 1417-1418, doi:10.1016/S0140-6736(20)30937-5 (2020).

10 Mehta, P. *et al.* COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* **395**, 1033-1034, doi:10.1016/S0140-6736(20)30628-0 (2020).

11 Bowles, L. *et al.* Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. *N Engl J Med*, doi:10.1056/NEJMc2013656 (2020).

12 Sevenet, P. O. & Depasse, F. Clot waveform analysis: Where do we stand in 2017? *Int J Lab Hematol* **39**, 561-568, doi:10.1111/ijlh.12724 (2017).

13 Solano, C., Zerafa, P. & Bird, R. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser. *International Journal of Laboratory Hematology* **33**, 67-78, doi:10.1111/j.1751-553X.2010.01248.x (2011).

14 Tokunaga, N. *et al.* Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies. *Blood Coagul Fibrinolysis* **27**, 474-476, doi:10.1097/MBC.0000000000000436 (2016).

15 Matsumoto, T. *et al.* An Evaluation of the Activated Partial Thromboplastin Time Waveform. *Clin Appl Thromb Hemost* **24**, 764-770, doi:10.1177/1076029617724230 (2018).

16 Tokutake, T. *et al.* Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients. *PLoS One* **11**, e0157835, doi:10.1371/journal.pone.0157835 (2016).
17 Toh, C. H. & Giles, A. R. Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). *Clin Lab Haematol* **24**, 321-327, doi:10.1046/j.1365-2257.2002.00457.x (2002).

18 Suzuki, K. *et al.* Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. *Thromb J* **17**, 12, doi:10.1186/s12959-019-0201-0 (2019).

19 Huck, V., Schneider, M. F., Gorzelanny, C. & Schneider, S. W. The various states of von Willebrand factor and their function in physiology and pathophysiology. *Thromb Haemost* **111**, 598-609, doi:10.1160/TH13-09-0800 (2014).

20 Koppelman, S. J. *et al.* Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. *Blood* **87**, 2292-2300 (1996).

21 Panigada, M. *et al.* Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. *J Thromb Haemost*, doi:10.1111/jth.14850 (2020).

22 Yan, B. *et al.* Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. *Viruses* **11**, doi:10.3390/v11010073 (2019).

**Declarations**

The current study was performed in accordance with the ethical guidelines of the Declaration of Helsinki. Informed consent was obtained in the form of an opt-out on the website. The study design was approved by The University of Tokyo Medical Research Center Ethics Committee (approval number, 3683).

**Data Availability Statement.**

The datasets generated or analyzed in the current study are available upon reasonable request.

**Acknowledgements:**

None.

**Authorship Contributions:**

T.S. participated in data analysis. M.K. participated in study design, data analysis, drafted the initial manuscript, and conceived of the study. M.N. were involved in study design and drafting manuscript. Y.K., M.I, K.O., D.J., S.H., and S.O. participated in discussion and helped to draft manuscript. K.M and Y.Y. conceived of the study, coordinated the study design and helped to draft the manuscript. All authors read and approved the final manuscript.
Competing Interests:

The authors declare no competing financial interests.

Tables

Table 1. Frequency of abnormal patterns of APTT second-derivative curves

|                | normal   | early | late | biphasic |
|----------------|----------|-------|------|----------|
| normal         | 100 % (n = 20) | 0 % (n = 0) | 0 % (n = 0) | 0 % (n = 0) |
| DIC            | 100 % (n = 11) | 0 % (n = 0) | 0 % (n = 0) | 0 % (n = 0) |
| warfarin       | 95 % (n = 19) | 0 % (n = 0) | 0 % (n = 0) | 5 % (n = 1) |
| heparin        | 100 % (n = 20) | 0 % (n = 0) | 0 % (n = 0) | 0 % (n = 0) |
| LA             | 0 % (n = 0) | 100 % (n = 2) | 0 % (n = 0) | 0 % (n = 0) |
| factor deficiency | 72 % (n = 5) | 14 % (n = 1) | 0 % (n = 0) | 14 % (n = 1) |
| COVID-19 (All) | 51 % (n = 70) | 5 % (n = 7) | 21 % (n = 29) | 23 % (n = 31) |
| COVID-19 (D-dimer) | 58 % (n = 15) | 4 % (n = 1) | 15 % (n = 4) | 23 % (n = 6) |
| COVID-19 (CRP) | 27 % (n = 7) | 4 % (n = 1) | 31 % (n = 8) | 38 % (n = 10) |
| COVID-19 (1st visit) | 35 % (n = 9) | 4 % (n = 1) | 27 % (n = 7) | 35 % (n = 9) |

$\chi^2 < 0.01$ for all the analytical models when all the APTT tests were analyzed together, when only the APTT tests performed at a time point corresponding to the maximum D-dimer or CRP level were analyzed, or when only the APPT tests performed at the time of each subject's initial visit to the hospital first were analyzed.

Table 2. Differences in the frequency of abnormal APTT second-derivative waveforms according to the severity of COVID-19 subjects

|                | normal   | early | late | biphasic |
|----------------|----------|-------|------|----------|
| mild case      | 62 % (n = 18) | 7 % (n = 2) | 17 % (n = 5) | 14 % (n = 4) |
| moderate case  | 48 % (n = 30) | 0 % (n = 0) | 24 % (n = 15) | 27 % (n = 17) |
| severe case    | 48 % (n = 22) | 11 % (n = 5) | 20 % (n = 9) | 22 % (n = 10) |

$\chi^2 < 0.01$

Figures
Figure 1

Representative APTT clot waveforms in COVID-19 and other subjects. Representative APTT clot waveforms in COVID-19 and other subjects are shown. (A) Normal subject, (B – D) COVID-19 subjects, (E) DIC subject, and (F) subject with lupus anti-coagulant.
Figure 2

A

First derivative peak max (mAbs/s)

normal  DIC  warfarin  heparin  LA  factor deficiency  COVID-19(All)  COVID-19(D-dimer)  COVID-19(CRP)  COVID-19(1st visit)

B

Second derivative peak max (mAbs/s^2)

normal  DIC  warfarin  heparin  LA  factor deficiency  COVID-19(All)  COVID-19(D-dimer)  COVID-19(CRP)  COVID-19(1st visit)

C

Second derivative peak min (mAbs/s^2)

normal  DIC  warfarin  heparin  LA  factor deficiency  COVID-19(All)  COVID-19(D-dimer)  COVID-19(CRP)  COVID-19(1st visit)
Parameters of APTT derivative curves for COVID-19 subjects. The maximum first-derivative peak (A), the maximum second-derivative peak (B), and the minimum second-derivative peak (C) for COVID-19 subjects are shown. COVID-19 (All), COVID-19 (D-dimer), COVID-19 (CRP), and COVID-19 (1st visit) represent the following data analyses: all APTT tests that were performed, APTT tests performed at time points corresponding to the maximum D-dimer or CRP level during each subject's time course, and APTT tests performed at the time of each subject's initial visit to the hospital, respectively. * P < 0.01 vs. normal, †P < 0.01 vs. other groups except LA, ‡P < 0.05 vs. normal, §P < 0.01 vs. other groups, ||P < 0.05 vs. other groups.
Figure 3

Differences in laboratory data related to coagulation among the patterns of APTT second-derivative curves. (A) APTT, (B) plasma fibrinogen levels, (C) D-dimer levels, and (D) CRP levels in specimens with normal, early shoulder, late shoulder, and biphasic patterns of APTT second-derivative curves. * P < 0.05 vs. normal, †P < 0.01 vs. normal
Figure 4
Correlations between parameters of APTT derivative curves and laboratory data related to coagulation in COVID-19 subjects. Correlations between the maximum first-derivative peak (A, D, G, J), the maximum second-derivative peak (B, E, H, K), and the minimum second-derivative peak (C, F, I, L) and APTT (A–C), fibrinogen (D–F), D-dimer (G–I), and CRP (J–L).
Figure 5

A. day 9
mAbsorbance
second

B. day 13
mAbsorbance
second

C. day 15
mAbsorbance
second

D. day 32
mAbsorbance
second

E. second (%)
~day 8 day 9~12 day 13~16 day 17~20 day 21~24 day 25~28 day 29~32 day 33~
n = 12 n = 24 n = 37 n = 27 n = 8 n = 15 n = 9 n = 5

F. First derivative peak max

G. Second derivative peak max

H. Second derivative peak min

Note: The figure shows absorbance data over time, with different stages marked and statistics provided.
Time course of the frequency of abnormal patterns and parameters of APTT derivative curves among COVID-19 subjects. (A–D) Time course of APTT clot waveforms in one COVID-19 subject. (E–H) Time course of the frequency of abnormal patterns and parameters of APTT derivative curves among COVID-19 subjects. * P < 0.05 vs. ≤ day 8, P < 0.01 vs. days 9-12 and days 13-16.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigureCOVIDcoagulaiton.pdf](#)